{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:24:39Z","timestamp":1792686279961,"version":"4.5.0"},"reference-count":72,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science Centre, Poland","award":["Sonata Bis 2019\/34\/E\/NZ7\/00056"],"award-info":[{"award-number":["Sonata Bis 2019\/34\/E\/NZ7\/00056"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Resistance to olaparib is the major obstacle in targeted therapy for ovarian cancer (OC) with poly(ADP-ribose) polymerase inhibitors (PARPis), prompting studies on novel combination therapies to enhance olaparib efficacy. Despite identifying various mechanisms, understanding how OC cells acquire PARPi resistance remains incomplete. This study investigated microRNA (miRNA) expression in olaparib-sensitive (PEO1, PEO4) and previously established olaparib-resistant OC cell lines (PEO1-OR) using high-throughput RT-qPCR and bioinformatic analyses. The role of miRNAs was explored regarding acquired resistance and resensitization with the ATR\/CHK1 pathway inhibitors. Differentially expressed miRNAs were used to construct miRNA\u2013mRNA regulatory networks and perform functional enrichment analyses for target genes with miRNet 2.0. TCGA-OV dataset was analyzed to explore the prognostic value of selected miRNAs and target genes in clinical samples. We identified potential processes associated with olaparib resistance, including cell proliferation, migration, cell cycle, and growth factor signaling. Resensitized PEO1-OR cells were enriched in growth factor signaling via PDGF, EGFR, FGFR1, VEGFR2, and TGF\u03b2R, regulation of the cell cycle via the G2\/M checkpoint, and caspase-mediated apoptosis. Antibody microarray analysis confirmed dysregulated growth factor expression. The addition of the ATR\/CHK1 pathway inhibitors to olaparib downregulated FGF4, FGF6, NT-4, PLGF, and TGF\u03b21 exclusively in PEO1-OR cells. Survival and differential expression analyses for serous OC patients revealed prognostic miRNAs likely associated with olaparib resistance (miR-99b-5p, miR-424-3p, and miR-505-5p) and resensitization to olaparib (miR-324-5p and miR-424-3p). Essential miRNA\u2013mRNA interactions were reconstructed based on prognostic miRNAs and target genes. In conclusion, our data highlight distinct miRNA profiles in olaparib-sensitive and olaparib-resistant cells, offering molecular insights into overcoming resistance with the ATR\/CHK1 inhibitors in OC. Moreover, some miRNAs might serve as potential predictive signature molecules of resistance and therapeutic response.<\/jats:p>","DOI":"10.3390\/cells13100867","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T09:10:22Z","timestamp":1715937022000},"page":"867","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Uncovering miRNA\u2013mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of BRCA2MUT Ovarian Cancer PEO1-OR Cells with the ATR\/CHK1 Pathway Inhibitors"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3896-8327","authenticated-orcid":false,"given":"\u0141ukasz","family":"Biega\u0142a","sequence":"first","affiliation":[{"name":"Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141\/143, 90-236 Lodz, Poland"},{"name":"Doctoral School of Exact and Natural Sciences, University of Lodz, Jana Matejki 21\/23, 90-237 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1086-3796","authenticated-orcid":false,"given":"Damian","family":"Ko\u0142at","sequence":"additional","affiliation":[{"name":"Department of Functional Genomics, Medical University of Lodz, \u017beligowskiego 7\/9, 90-752 Lodz, Poland"},{"name":"Department of Biomedicine and Experimental Surgery, Medical University of Lodz, Narutowicza 60, 90-136 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3475-441X","authenticated-orcid":false,"given":"Arkadiusz","family":"Gajek","sequence":"additional","affiliation":[{"name":"Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141\/143, 90-236 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6682-0402","authenticated-orcid":false,"given":"El\u017cbieta","family":"P\u0142uciennik","sequence":"additional","affiliation":[{"name":"Department of Functional Genomics, Medical University of Lodz, \u017beligowskiego 7\/9, 90-752 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3439-9032","authenticated-orcid":false,"given":"Agnieszka","family":"Marczak","sequence":"additional","affiliation":[{"name":"Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141\/143, 90-236 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6864-0704","authenticated-orcid":false,"given":"Agnieszka","family":"\u015aliwi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Nucleic Acid Biochemistry, Medical University of Lodz, Pomorska 251, 92-213 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-7328","authenticated-orcid":false,"given":"Micha\u0142","family":"Mikula","sequence":"additional","affiliation":[{"name":"Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4170-1693","authenticated-orcid":false,"given":"Aneta","family":"Rogalska","sequence":"additional","affiliation":[{"name":"Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141\/143, 90-236 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1200\/JCO.20.00799","article-title":"Efficacy of Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer with a BRCA Mutation: Subgroup Analysis Findings from the SOLO1 Trial","volume":"38","author":"DiSilvestro","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lisio, M.A., Fu, L., Goyeneche, A., Gao, Z.H., and Telleria, C. (2019). High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040952"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"858826","DOI":"10.3389\/fonc.2022.858826","article-title":"Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"967633","DOI":"10.3389\/fphar.2022.967633","article-title":"PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41416-023-02567-6","article-title":"Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer","volume":"130","author":"Nicum","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1200\/PO.20.00439","article-title":"Ceralasertib-Mediated ATR Inhibition Combined with Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)","volume":"5","author":"Mahdi","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"22659","DOI":"10.1038\/s41598-023-50151-y","article-title":"Targeted inhibition of the ATR\/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2MUT ovarian cancer cells","volume":"13","author":"Biegala","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"McMullen, M., Karakasis, K., Madariaga, A., and Oza, A.M. (2020). Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer. Cancers, 12.","DOI":"10.3390\/cancers12061607"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Burgess, B.T., Anderson, A.M., McCorkle, J.R., Wu, J., Ueland, F.R., and Kolesar, J.M. (2020). Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells. Diagnostics, 10.","DOI":"10.3390\/diagnostics10020121"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","article-title":"Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer","volume":"29","author":"Wethington","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.gendis.2021.12.026","article-title":"Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine","volume":"9","author":"Kandettu","year":"2022","journal-title":"Genes Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1007\/s43032-021-00717-w","article-title":"The Role of miRNA in Ovarian Cancer: An Overview","volume":"29","author":"Zhao","year":"2022","journal-title":"Reprod. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Frisk, N.L.S., Sorensen, A.E., Pedersen, O.B.V., and Dalgaard, L.T. (2023). Circulating microRNAs for Early Diagnosis of Ovarian Cancer: A Systematic Review and Meta-Analysis. Biomolecules, 13.","DOI":"10.3390\/biom13050871"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1038\/s41467-018-06434-4","article-title":"Integrated extracellular microRNA profiling for ovarian cancer screening","volume":"9","author":"Yokoi","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1111\/jcmm.17477","article-title":"Construction of miRNA-lncRNA-mRNA co-expression network affecting EMT-mediated cisplatin resistance in ovarian cancer","volume":"26","author":"Dehghanian","year":"2022","journal-title":"J. Cell Mol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41419-018-0390-7","article-title":"miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1","volume":"9","author":"Wang","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Biegala, L., Gajek, A., Marczak, A., and Rogalska, A. (2023). Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2\/M Arrest Controlled by the ATR\/CHK1 Pathway for Survival. Cells, 12.","DOI":"10.3390\/cells12071038"},{"key":"ref_18","first-page":"6166","article-title":"Characterization and properties of nine human ovarian adenocarcinoma cell lines","volume":"48","author":"Langdon","year":"1988","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1038\/onc.2010.245","article-title":"Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma","volume":"29","author":"Cooke","year":"2010","journal-title":"Oncogene"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative CT method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mestdagh, P., Van Vlierberghe, P., De Weer, A., Muth, D., Westermann, F., Speleman, F., and Vandesompele, J. (2009). A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol., 10.","DOI":"10.1186\/gb-2009-10-6-r64"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"836636","DOI":"10.3389\/fgene.2022.836636","article-title":"Comparison of Data Normalization Strategies for Array-Based MicroRNA Profiling Experiments and Identification and Validation of Circulating MicroRNAs as Endogenous Controls in Hypertension","volume":"13","author":"Chekka","year":"2022","journal-title":"Front. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1261\/rna.1295509","article-title":"Impact of normalization on miRNA microarray expression profiling","volume":"15","author":"Pradervand","year":"2009","journal-title":"RNA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/ng.2007.30","article-title":"Widespread microRNA repression by Myc contributes to tumorigenesis","volume":"40","author":"Chang","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Guo, Y., Zhang, Y., Zhang, S.J., Ma, Y.N., and He, Y. (2019). Comprehensive analysis of key genes and microRNAs in radioresistant nasopharyngeal carcinoma. BMC Med. Genom., 12.","DOI":"10.1186\/s12920-019-0507-6"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Licursi, V., Conte, F., Fiscon, G., and Paci, P. (2019). MIENTURNET: An interactive web tool for microRNA-target enrichment and network-based analysis. BMC Bioinform., 20.","DOI":"10.1186\/s12859-019-3105-x"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"D296","DOI":"10.1093\/nar\/gkx1067","article-title":"miRTarBase update 2018: A resource for experimentally validated microRNA-target interactions","volume":"46","author":"Chou","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"W566","DOI":"10.1093\/nar\/gkv468","article-title":"ClustVis: A web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap","volume":"43","author":"Metsalu","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"W244","DOI":"10.1093\/nar\/gkaa467","article-title":"miRNet 2.0: Network-based visual analytics for miRNA functional analysis and systems biology","volume":"48","author":"Chang","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: Ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/ijgc-2021-002462","article-title":"The role of radiotherapy in ovarian cancer","volume":"32","author":"Durno","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"P248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: Pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Bartha, A., and Gyorffy, B. (2021). TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052622"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"104190","DOI":"10.1016\/j.isci.2022.104190","article-title":"ToPP: Tumor online prognostic analysis platform for prognostic feature selection and clinical patient subgroup selection","volume":"25","author":"Ouyang","year":"2022","journal-title":"iScience"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/0008-5472.CAN-14-2593","article-title":"A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance","volume":"75","author":"Ceccaldi","year":"2015","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"17588359231157644","DOI":"10.1177\/17588359231157644","article-title":"Fighting resistance: Post-PARP inhibitor treatment strategies in ovarian cancer","volume":"15","author":"Veneziani","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13148-019-0758-2","article-title":"Histone methyltransferases EHMT1 and EHMT2 (GLP\/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma","volume":"11","author":"Watson","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"70524","DOI":"10.18632\/oncotarget.12045","article-title":"Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue","volume":"7","author":"Nam","year":"2016","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/s41416-022-01899-z","article-title":"Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer","volume":"127","author":"Nicholson","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Zhao, J., Tan, W., Zhang, L., Liu, J., Shangguan, M., Chen, J., Zhao, B., Peng, Y., Cui, M., and Zhao, S. (2021). FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer. Biochem. Pharmacol., 190.","DOI":"10.1016\/j.bcp.2021.114536"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10585-021-10077-z","article-title":"TGFbeta signaling networks in ovarian cancer progression and plasticity","volume":"38","author":"Kumari","year":"2021","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"12855","DOI":"10.1093\/nar\/gkab1184","article-title":"Loss of MED12 activates the TGFbeta pathway to promote chemoresistance and replication fork stability in BRCA-deficient cells","volume":"49","author":"Jackson","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"108221","DOI":"10.1016\/j.celrep.2020.108221","article-title":"TGF\u03b2R-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment","volume":"33","author":"Le","year":"2020","journal-title":"Cell Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s12935-019-1051-3","article-title":"Cancer-associated fibroblast-derived exosomal microRNA-98-5p promotes cisplatin resistance in ovarian cancer by targeting CDKN1A","volume":"19","author":"Guo","year":"2019","journal-title":"Cancer Cell Int."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Deng, J., Bai, X., Feng, X., Ni, J., Beretov, J., Graham, P., and Li, Y. (2019). Inhibition of PI3K\/Akt\/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5824-9"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00280-022-04403-9","article-title":"An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer","volume":"89","author":"Xu","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"28609","DOI":"10.1074\/jbc.M703796200","article-title":"EF24 induces G2\/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression","volume":"282","author":"Selvendiran","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","article-title":"An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"ref_53","first-page":"5601","article-title":"MicroRNA profiling of plasma exosomes from patients with ovarian cancer using high-throughput sequencing","volume":"17","author":"Zhang","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1084\/jem.20180765","article-title":"Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer","volume":"216","author":"Gao","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00404-018-4999-7","article-title":"MiR-424-3p suppresses galectin-3 expression and sensitizes ovarian cancer cells to cisplatin","volume":"299","author":"Bieg","year":"2019","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"12522","DOI":"10.1038\/s41598-018-30978-6","article-title":"Novel oncogenic and chemoresistance-inducing functions of resistin in ovarian cancer cells require miRNAs-mediated induction of epithelial-to-mesenchymal transition","volume":"8","author":"Qiu","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/jcp.26114","article-title":"The ubiquitin ligase TRIM56 inhibits ovarian cancer progression by targeting vimentin","volume":"233","author":"Zhao","year":"2018","journal-title":"J. Cell Physiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.15252\/emmm.201607012","article-title":"CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation","volume":"9","author":"Sonego","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13046-019-1490-7","article-title":"MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1","volume":"39","author":"Vescarelli","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1535370221994077","article-title":"Enhancing the sensitivity of ovarian cancer cells to olaparib via microRNA-20b-mediated cyclin D1 targeting","volume":"246","author":"Zhong","year":"2021","journal-title":"Exp. Biol. Med."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Roberts, C.M., Rojas-Alexandre, M., Hanna, R.E., Lin, Z.P., and Ratner, E.S. (2023). Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib. Cancers, 15.","DOI":"10.20944\/preprints202304.0327.v1"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1074\/jbc.M111.317529","article-title":"Regulation of the ligand-dependent activation of the epidermal growth factor receptor by calmodulin","volume":"287","author":"Li","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e3428","DOI":"10.17795\/ijcp-3428","article-title":"Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) in Patients With Serous Ovarian Carcinoma and Their Clinical Significance","volume":"8","author":"Ranjbar","year":"2015","journal-title":"Iran. J. Cancer Prev."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Huang, D., Ke, L., Cui, H., Li, S., and Sun, F. (2024). Efficacy and safety of VEGF\/VEGFR inhibitors for platinum-resistant ovarian cancer: A systematic review and meta-analysis of randomized controlled trials. BMC Womens Health, 24.","DOI":"10.1186\/s12905-023-02879-y"},{"key":"ref_65","first-page":"326","article-title":"14-3-3sigma, the double-edged sword of human cancers","volume":"1","author":"Li","year":"2009","journal-title":"Am. J. Transl. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1158\/1078-0432.CCR-03-0510","article-title":"Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: Its correlation with aberrant DNA methylation","volume":"10","author":"Akahira","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/labinvest.2014.122","article-title":"Fibroblasts induce expression of FGF4 in ovarian cancer stem-like cells\/cancer-initiating cells and upregulate their tumor initiation capacity","volume":"94","author":"Yasuda","year":"2014","journal-title":"Lab. Investig."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.3892\/ol.2016.5226","article-title":"PARP-1 may be involved in angiogenesis in epithelial ovarian cancer","volume":"12","author":"Wei","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Wang, Y., Xiang, J., Wang, J., and Ji, Y. (2018). Downregulation of TGF-\u03b21 suppressed proliferation and increased chemosensitivity of ovarian cancer cells by promoting BRCA1\/Smad3 signaling. Biol. Res., 51.","DOI":"10.1186\/s40659-018-0205-4"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Usman, S., Waseem, N.H., Nguyen, T.K.N., Mohsin, S., Jamal, A., Teh, M.T., and Waseem, A. (2021). Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis. Cancers, 13.","DOI":"10.3390\/cancers13194985"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.pharep.2016.08.001","article-title":"Effects of PARP-1 inhibitor and ERK inhibitor on epithelial mesenchymal transitions of the ovarian cancer SKOV3 cells","volume":"68","author":"Su","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.4143\/crt.2018.405","article-title":"Genetic Profiles Associated with Chemoresistance in Patient-Derived Xenograft Models of Ovarian Cancer","volume":"51","author":"Li","year":"2019","journal-title":"Cancer Res. Treat."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/10\/867\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:44:07Z","timestamp":1760107447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/10\/867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":72,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["cells13100867"],"URL":"https:\/\/doi.org\/10.3390\/cells13100867","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]}}}